Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines

Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines

Bibliographic Details
Main Authors:	Nadler LM, Fiore F, Maecker B, von Bergwelt-Baildon MS, Schultze JL
Format:	Article
Language:	English
Published:	BMC 2004-07-01
Series:	Cancer Cell International

Similar Items

Increased frequency of CTLA4<sup>+ </sup>TGFβ<sup>+ </sup>CD4<sup>+ </sup>CD25<sup>+ </sup>T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma
by: Schultze JL, et al.
Published: (2004-07-01)

Studies on CD40mAb-adjuvanted conjugate vaccines
by: Sultana, Tessabelle
Published: (2014)

Assessment of anti- CD40 monoclonal antibodies as novel immunological adjuvants in conjugate vaccines
by: Heath, Andrew
Published: (2008)

Assessment of Anti-CD40 Monoclonal Antibodies as Novel Immunological Adjuvants in Conjuate Vaccines
by: Prasad, Vijay Narayana Sharma Bhagawati
Published: (2008)

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells
by: Shimabukuro-Vornhagen Alexander, et al.
Published: (2012-05-01)

P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine
by: Ostrowski MA, et al.
Published: (2009-10-01)

Investigation into the use of feline CD40 ligand as an adjuvant in a DNA vaccine against feline immunodeficiency virus
by: Brown, Abigail Louise
Published: (2004)

MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.
by: Matthew R Collinson-Pautz, et al.
Published: (2016-01-01)

Prerequisites and opportunities for repositioning of the Urals metallurgy within the Industry 4.0
by: O. A. Romanova, et al.
Published: (2017-12-01)

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
by: Karlyn E Pollack, et al.
Published: (2020-06-01)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
by: Kwa S, et al.
Published: (2012-09-01)

Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant
by: Yan Cao, et al.
Published: (2018-09-01)

Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity
by: Karen A.O. Martins, et al.
Published: (2016-01-01)

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.
by: Andreas Draube, et al.
Published: (2011-01-01)

Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults
by: Christine M. D. Lingblom, et al.
Published: (2018-06-01)

Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant.
by: Cameron Martin, et al.
Published: (2017-01-01)

Adjuvants for Coronavirus Vaccines
by: Zhihui Liang, et al.
Published: (2020-11-01)

Novel Vaccine Adjuvants
by: Anshu Agrawal, et al.
Published: (2013-01-01)

Overview of vaccine adjuvants
by: Zhenchuan Wu, et al.
Published: (2021-09-01)

Adjuvant induced cellular cytotoxicity
by: Gray, J. D.
Published: (1981)

Green propolis phenolic compounds act as vaccine adjuvants, improving humoral and cellular responses in mice inoculated with inactivated vaccines
by: Geferson Fischer, et al.
Published: (2010-11-01)

Evaluation of cellular and humeral immune response of sheep vaccinated with inactivated Rift Valley Fever vaccine adjuvanted with Montanide Gel
by: Abd El Rahman S.E., et al.
Published: (2020-01-01)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
by: Lisa Rohrbacher, et al.
Published: (2021-03-01)

An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21
by: Carter, D., et al.
Published: (2022)

Vaccine adjuvant informatics: from data integration and analysis to rational vaccine adjuvant design
by: Yongqun Oliver eHe
Published: (2014-02-01)

Different biological activity of CD154-SIVgp41 fusion protein vaccine component in naïve or pre-immune individuals
by: Smith LM, et al.
Published: (2012-09-01)

Vaccines with adjuvants. Preclinical studies
by: Zh. I. Avdeeva, et al.
Published: (2018-02-01)

Inorganic compounds as vaccine adjuvants
by: Armando A Paneque-Quevedo

Chemokines as Cancer Vaccine Adjuvants
by: Agne Petrosiute, et al.
Published: (2013-10-01)

Vaccine adjuvants: mode of action
by: Jeffrey eUlmer
Published: (2013-07-01)

Vaccine Potentiation by Combination Adjuvants
by: Benoît Levast, et al.
Published: (2014-04-01)

The immunological effect of vaccine adjuvants
by: Chin-An Wu, et al.
Published: (2003)

Effects of vaccine adjuvant on hematopoiesis
by: Kai-Wen Cheng, et al.
Published: (2016)

A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.
by: Laura Pattacini, et al.
Published: (2012-01-01)

Immunity against avian influenza H5N1 viruses using DNA vaccines encoding CD40L, Flt3L and GM-CSF as molecular adjuvants
by: 白雅如
Published: (2012)

Combined adjuvant for stimulation of cellular immunity
by: Tye, Gee Jun
Published: (2012)

Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
by: Li Y, et al.
Published: (2014-12-01)

Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development
by: Samantha Sayers, et al.
Published: (2012-01-01)

The Role of CD40L and CD40 in the Pathogenesis of Kawasaki Disease
by: Arjmand, Parnian
Published: (2011)

The Role of CD40L and CD40 in the Pathogenesis of Kawasaki Disease
by: Arjmand, Parnian
Published: (2011)